X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (8085) 8085
Book Review (1393) 1393
Publication (589) 589
Newsletter (54) 54
Magazine Article (27) 27
Conference Proceeding (21) 21
Book Chapter (17) 17
Newspaper Article (8) 8
Report (2) 2
Dissertation (1) 1
Reference (1) 1
Trade Publication Article (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (7335) 7335
index medicus (6985) 6985
lamivudine (4210) 4210
lamivudine - therapeutic use (4203) 4203
male (4095) 4095
female (3919) 3919
adult (3716) 3716
antiviral agents - therapeutic use (3258) 3258
middle aged (2818) 2818
hepatitis b, chronic - drug therapy (2608) 2608
hiv infections - drug therapy (2329) 2329
treatment outcome (1976) 1976
infectious diseases (1927) 1927
gastroenterology & hepatology (1904) 1904
hepatitis b (1886) 1886
anti-hiv agents - therapeutic use (1865) 1865
drug therapy, combination (1781) 1781
reverse transcriptase inhibitors - therapeutic use (1655) 1655
hepatitis b virus - genetics (1514) 1514
therapy (1460) 1460
viral load (1362) 1362
virology (1343) 1343
hepatitis b virus (1271) 1271
adenine - analogs & derivatives (1249) 1249
infection (1214) 1214
hepatitis b virus - drug effects (1193) 1193
hiv (1190) 1190
pharmacology & pharmacy (1147) 1147
aids/hiv (1128) 1128
adenine - therapeutic use (1105) 1105
immunology (1070) 1070
dna, viral - blood (1050) 1050
aged (1046) 1046
hepatitis b, chronic - virology (1000) 1000
drug therapy (998) 998
hepatitis b - drug therapy (997) 997
tenofovir (994) 994
zidovudine - therapeutic use (994) 994
organophosphonates - therapeutic use (979) 979
mutation (973) 973
antiviral agents (915) 915
lamivudine - administration & dosage (863) 863
adefovir dipivoxil (826) 826
hiv infections - virology (824) 824
hepatitis (811) 811
adolescent (806) 806
health aspects (792) 792
drug resistance, viral (773) 773
hepatitis b e antigens - blood (762) 762
retrospective studies (762) 762
antiretroviral therapy (715) 715
cd4 lymphocyte count (710) 710
guanine - analogs & derivatives (705) 705
zidovudine (702) 702
entecavir (677) 677
time factors (655) 655
resistance (653) 653
abridged index medicus (628) 628
care and treatment (627) 627
guanine - therapeutic use (624) 624
interferon-alpha - therapeutic use (623) 623
young adult (618) 618
chronic hepatitis b (617) 617
hiv-1 - drug effects (610) 610
interferon (610) 610
genotype (605) 605
microbiology (599) 599
drug resistance (596) 596
risk factors (568) 568
lamivudine - pharmacology (564) 564
efficacy (547) 547
human immunodeficiency virus--hiv (544) 544
lamivudine - adverse effects (543) 543
dna (542) 542
analysis (540) 540
transplantation (533) 533
hiv infection (530) 530
virus-infection (529) 529
hepatitis b surface antigens - blood (527) 527
follow-up studies (525) 525
research (521) 521
antiretroviral drugs (515) 515
hepatitis b virus - immunology (506) 506
recurrence (503) 503
hepatocellular-carcinoma (493) 493
antiviral agents - administration & dosage (492) 492
antiviral agents - pharmacology (492) 492
liver transplantation (492) 492
drug resistance, viral - genetics (488) 488
hepatitis b, chronic - complications (486) 486
virus diseases (486) 486
combination (483) 483
hiv protease inhibitors - therapeutic use (483) 483
antiretroviral therapy, highly active (479) 479
hiv-1 - genetics (468) 468
anti-hiv agents - adverse effects (465) 465
anti-hiv agents - administration & dosage (463) 463
prospective studies (462) 462
virus (461) 461
medicine, general & internal (460) 460
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (7543) 7543
Chinese (224) 224
French (99) 99
Spanish (88) 88
German (56) 56
Korean (46) 46
Japanese (43) 43
Polish (18) 18
Hungarian (12) 12
Turkish (12) 12
Russian (11) 11
Dutch (9) 9
Italian (8) 8
Portuguese (7) 7
Czech (5) 5
Danish (3) 3
Romanian (3) 3
Serbian (3) 3
Croatian (2) 2
Finnish (1) 1
Hebrew (1) 1
Lithuanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Infectious Diseases, The, ISSN 1473-3099, 2015, Volume 15, Issue 7, pp. 775 - 784
Summary Background Problems associated with lifelong antiretroviral therapy, such as need for strict adherence, drug-related toxic effects, difficulties with... 
Infectious Disease | INFECTIOUS DISEASES | ABACAVIR-LAMIVUDINE | EFFICACY | SAFETY | NAIVE HIV-1-INFECTED PATIENTS | ACTIVE ANTIRETROVIRAL THERAPY | ONCE-DAILY ATAZANAVIR/RITONAVIR | TWICE-DAILY LOPINAVIR/RITONAVIR | INFECTED PATIENTS | PROTEASE INHIBITORS | TENOFOVIR | HIV-1 | Humans | Middle Aged | Male | RNA, Viral - blood | Viral Load | Oligopeptides - therapeutic use | Reverse Transcriptase Inhibitors - adverse effects | Tenofovir | Deoxycytidine - therapeutic use | Drug Therapy, Combination - adverse effects | Adenine - therapeutic use | Lamivudine - therapeutic use | Atazanavir Sulfate | Ritonavir - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Reverse Transcriptase Inhibitors - therapeutic use | Pyridines - therapeutic use | Emtricitabine | HIV Protease Inhibitors - adverse effects | Adenine - analogs & derivatives | Organophosphonates - therapeutic use | Anti-HIV Agents - adverse effects | HIV Infections - virology | HIV Protease Inhibitors - therapeutic use | Drug Therapy, Combination - methods | HIV Infections - drug therapy | Zidovudine - therapeutic use | Drug Substitution | Deoxycytidine - analogs & derivatives | Studies | Antiretroviral drugs | Heart attacks | Protease inhibitors | Acquired immune deficiency syndrome--AIDS | Human immunodeficiency virus--HIV | Clinical trials | Infections | Mutation | Drug therapy | Failure | Cost control | Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9787, pp. 229 - 237
Summary Background The non-nucleoside reverse transcriptase inhibitor (NNRTI), rilpivirine (TMC278; Tibotec Pharmaceuticals, County Cork, Ireland), had... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | ZIDOVUDINE | COMBINATION THERAPY | ACTIVE ANTIRETROVIRAL THERAPY | EMTRICITABINE | PROTEASE-INHIBITOR | CYSTATIN-C | CREATININE | DAILY LAMIVUDINE | NEVIRAPINE | TENOFOVIR | Rilpivirine | HIV Reverse Transcriptase - antagonists & inhibitors | Humans | Middle Aged | Male | Anti-HIV Agents - administration & dosage | Nitriles - administration & dosage | Tenofovir | Deoxycytidine - therapeutic use | Nucleotides - therapeutic use | Adenine - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Reverse Transcriptase Inhibitors - therapeutic use | Acquired Immunodeficiency Syndrome - virology | Acquired Immunodeficiency Syndrome - ethnology | Emtricitabine | Nucleosides - therapeutic use | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Double-Blind Method | Drug Administration Schedule | Organophosphonates - therapeutic use | HIV-1 - drug effects | Pyrimidines - administration & dosage | Anti-HIV Agents - adverse effects | Benzoxazines - adverse effects | Treatment Outcome | HIV-1 - genetics | Acquired Immunodeficiency Syndrome - drug therapy | Benzoxazines - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Mutation | Nitriles - adverse effects | Viral Load - drug effects | Deoxycytidine - analogs & derivatives | Nitriles - therapeutic use | Evaluation | Patient outcomes | Clinical trials | Dosage and administration | Drug therapy | HIV infection | Design | Antiretroviral drugs | Corporate sponsorship | Human immunodeficiency virus--HIV | Technological change | Research | Clinical medicine | Drugs | RNA-directed DNA polymerase | Exanthema | antiretroviral therapy | Lamivudine | Lipids | Nucleotides | Regression analysis | Efavirenz | CD4 antigen | nucleosides | Algorithms | Hospitals | non-nucleoside reverse transcriptase inhibitors | Abacavir | Zidovudine | Pharmaceuticals | Index Medicus | Abridged Index Medicus
Journal Article
The Lancet, ISSN 0140-6736, 09/2017, Volume 390, Issue 10101, pp. 1499 - 1510
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9787, pp. 238 - 246
Summary Background Efavirenz with tenofovir-disoproxil-fumarate and emtricitabine is a preferred antiretroviral regimen for treatment-naive patients infected... 
Internal Medicine | LAMIVUDINE | MEDICINE, GENERAL & INTERNAL | EFFICACY | SAFETY | COMBINATION THERAPY | GUIDELINES | PROTEASE-INHIBITOR | ANTIRETROVIRAL THERAPY | NEVIRAPINE | REGIMENS | Rilpivirine | HIV Reverse Transcriptase - antagonists & inhibitors | Humans | Middle Aged | Male | Anti-HIV Agents - administration & dosage | Nitriles - administration & dosage | Tenofovir | Deoxycytidine - therapeutic use | Adenine - adverse effects | Adenine - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Reverse Transcriptase Inhibitors - therapeutic use | Acquired Immunodeficiency Syndrome - virology | Acquired Immunodeficiency Syndrome - ethnology | Emtricitabine | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Double-Blind Method | Drug Administration Schedule | Organophosphonates - therapeutic use | HIV-1 - drug effects | Pyrimidines - administration & dosage | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | Organophosphonates - adverse effects | Benzoxazines - adverse effects | Treatment Outcome | HIV-1 - genetics | Acquired Immunodeficiency Syndrome - drug therapy | Adenine - administration & dosage | Benzoxazines - therapeutic use | Organophosphonates - administration & dosage | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Aged | Mutation | Nitriles - adverse effects | Viral Load - drug effects | Deoxycytidine - analogs & derivatives | Nitriles - therapeutic use | Dosage and administration | Efavirenz | Patient outcomes | Clinical trials | Antiretroviral drugs | Drug therapy | Human immunodeficiency virus--HIV | Index Medicus | Abridged Index Medicus
Journal Article
AIDS, ISSN 0269-9370, 01/2015, Volume 29, Issue 2, pp. 167 - 174
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2015, Volume 15, Issue 7, pp. 785 - 792
Journal Article
Journal of Infectious Diseases, ISSN 0022-1899, 10/2015, Volume 212, Issue 8, pp. 1241 - 1249
Background. Specific antiretroviral therapy (ART) medications and the severity of human immunodeficiency virus (HIV) disease before treatment contribute to... 
human immunodeficiency virus | bone mineral density | protease inhibitor | inflammation | integrase inhibitor | INTIMA-MEDIA THICKNESS | INFECTIOUS DISEASES | ABACAVIR-LAMIVUDINE | TURNOVER | EMTRICITABINE | MICROBIOLOGY | OSTEOPROTEGERIN | IMMUNOLOGY | HIV-INFECTED ADULTS | PROTEASE INHIBITORS | THERAPY | RECEPTOR ACTIVATOR | Raltegravir Potassium - adverse effects | Humans | Middle Aged | Raltegravir Potassium - therapeutic use | Male | Atazanavir Sulfate - adverse effects | HIV - drug effects | Viral Load | Reverse Transcriptase Inhibitors - adverse effects | Young Adult | Ritonavir - adverse effects | Ritonavir - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Reverse Transcriptase Inhibitors - therapeutic use | Drug Therapy, Combination | HIV Protease Inhibitors - adverse effects | Emtricitabine - adverse effects | Emtricitabine - therapeutic use | Tenofovir - adverse effects | Tenofovir - therapeutic use | Anti-HIV Agents - adverse effects | HIV Protease Inhibitors - therapeutic use | Atazanavir Sulfate - therapeutic use | Bone Density - drug effects | HIV Integrase Inhibitors - adverse effects | HIV Integrase Inhibitors - therapeutic use | HIV Infections - drug therapy | Darunavir - adverse effects | HIV Infections - physiopathology | Darunavir - therapeutic use | Antiviral agents | Care and treatment | Analysis | Bones | Dosage and administration | Inflammation | HIV infection | Density | Risk factors | Index Medicus | Abridged Index Medicus | Major and Brief Reports
Journal Article
Journal Article
The Lancet, ISSN 0140-6736, 2006, Volume 368, Issue 9534, pp. 476 - 482
Lopinavir-ritonavir is a preferred protease inhibitor co-formulation for initial HIV-1 treatment. Fosamprenavir-ritonavir has shown similar efficacy and safety... 
MEDICINE, GENERAL & INTERNAL | THERAPY | NAIVE PATIENTS | RECOMMENDATIONS | EFAVIRENZ | TENOFOVIR DF | RESISTANCE | AIDS | SOCIETY-USA PANEL | LOPINAVIR/RITONAVIR | NELFINAVIR | Dideoxynucleosides - administration & dosage | Organophosphates - administration & dosage | Lamivudine - administration & dosage | Ritonavir - administration & dosage | HIV-1 - drug effects | Humans | Lopinavir | Pyrimidinones - therapeutic use | Organophosphates - therapeutic use | Carbamates - administration & dosage | HIV Protease Inhibitors - administration & dosage | HIV-1 - genetics | Reverse Transcriptase Inhibitors - administration & dosage | HIV Protease Inhibitors - therapeutic use | Sulfonamides - therapeutic use | Lamivudine - therapeutic use | Ritonavir - therapeutic use | HIV Infections - drug therapy | Dideoxynucleosides - therapeutic use | Pyrimidinones - administration & dosage | Reverse Transcriptase Inhibitors - therapeutic use | Carbamates - therapeutic use | Drug Therapy, Combination | Sulfonamides - administration & dosage | Dosage and administration | Protease inhibitors | Comparative analysis | Drug therapy | HIV infection | Antiviral agents | Research | Drug therapy, Combination | Health aspects | Anti-HIV agents | Antiretroviral drugs | Human immunodeficiency virus--HIV | Samples | Clinical trials | Comparative studies | Clinical medicine | Disease control | Index Medicus | Abridged Index Medicus
Journal Article
AIDS, ISSN 0269-9370, 07/2009, Volume 23, Issue 12, pp. 1547 - 1556
Background: Abacavir sulfate/lamivudine (ABC/3TC) and tenofovir DF/emtricitabine (TDF/FTC) are widely used nucleoside reverse transcriptase inhibitors for... 
Emtricitabine | Tenofovir | Ritonavir | Lopinavir | Abacavir | Lamivudine | Antiretroviral therapy | emtricitabine | INFECTIOUS DISEASES | MYOCARDIAL-INFARCTION | tenofovir | antiretroviral therapy | NAIVE HIV-1-INFECTED PATIENTS | IMMUNOLOGY | REVERSE-TRANSCRIPTASE INHIBITORS | VIROLOGY | lopinavir | ritonavir | RENAL-FAILURE | abacavir | SOCIETY-USA PANEL | INFECTED PATIENTS | 2008 RECOMMENDATIONS | FANCONI-SYNDROME | lamivudine | Humans | Antiretroviral Therapy, Highly Active - adverse effects | Male | RNA, Viral - blood | Lamivudine - adverse effects | HIV Infections - immunology | Deoxycytidine - therapeutic use | Adenine - adverse effects | Ritonavir - adverse effects | Adenine - therapeutic use | HIV-1 - isolation & purification | Lamivudine - therapeutic use | Ritonavir - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Dideoxynucleosides - adverse effects | Dideoxynucleosides - therapeutic use | Antiretroviral Therapy, Highly Active - methods | Adenine - analogs & derivatives | Double-Blind Method | Organophosphonates - therapeutic use | Anti-HIV Agents - adverse effects | HIV Infections - virology | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Organophosphonates - adverse effects | Treatment Outcome | CD4 Lymphocyte Count | HIV-1 - genetics | HIV Infections - drug therapy | Cardiovascular Diseases - chemically induced | Deoxycytidine - analogs & derivatives | Index Medicus | AIDS/HIV
Journal Article